Recursion CEO Najat Khan 4Q/FY25 Earnings Recap

This is the era of proof points. In this video, Recursion CEO and President Najat Khan shares key highlights from Recursion’s recent 4Q/FY25 earnings call. They include: 🔹 Positive Phase 2 data in FAP, a rare disease with no approved medicines. Our platform identified MEK1/2 inhibition as a novel mechanism and therapeutic entry point. We took that insight into the clinic, and the data we shared in December shows meaningful patient outcomes. 🔹 A 5th milestone with Sanofi, generating a $4 million payment to Recursion, and over $134 million in milestone and upfront payments to date. This collaboration leverages our generative chemistry platform to establish a growing joint portfolio of novel AI-driven small molecules for immunology and oncology. 🔹 New preclinical data from one of our oncology programs, REC-7735, a potentially best-in-class PI3Kα inhibitor. This compound was precision-designed using our generative chemistry platform to maximize selectivity and limit potential tolerability issues. We’re pairing bold ambition with operational rigor and financial discipline – and extended our cash runway into early 2028, with $754 million in cash. 👉 Check out the full earnings presentation: https://ir.recursion.com/static-files/6f8975ea-9c4f-4aff-b71c-ec4e870bc50e #earnings #financial #TechBio #AI #drugdiscovery